BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

Small molecule Bcl-xL inhibitorsand Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the t...

Full description

Saved in:
Bibliographic Details
Main Authors Zhi-Fu TAO, Robin R. FREY, Aaron R. KUNZER, Xilu WANG, Steve C. CULLEN, Anthony R. HAIGHT, Dennie S. WELCH, Nathan B. BENNETT, Michael D. WENDT, Xiaoqiang SHEN, Xiaohong SONG, Gerard M. SULLIVAN, Erwin R. BOGHAERT, Scott L. ACKLER, Andrew J. SOUERS, George DOHERTY, Andrew S. JUDD
Format Patent
LanguageEnglish
Spanish
Published 05.09.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Small molecule Bcl-xL inhibitorsand Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway. En la presente se dan a conocer inhibidores de BcI-xL de molécula pequeña y conjugados de anticuerpo-fármaco (ADC) que comprenden los inhibidores de Bcl-xL de molécula pequeña. Los inhibidores de Bcl-xL y los ADC de la invención son útiles, entre otras cosas, para inhibir las proteínas Bcl-xL anti-apoptóticas como un planteamiento terapéutico para el tratamiento de enfermedades que involucran una senda de apoptosis mal regulada.
Bibliography:Application Number: MX20170007637